Development tracker: The drugs and vaccines in development for COVID-19

The pharmaceutical and biopharmaceutical industry is scrambling to put products into development to potentially treat, cure or prevent COVID-19 .

Based on a review by AgencyIQ of ClinicalTrials.gov, company announcements and media reports, there are at least 140 medical product candidates in various stages of testing to assess their potential effects against COVID-19 or SARS-CoV-2, the virus which causes the condition. Some have already been approved and are being assessed for their potential to treat COVID, while others are being repurposed from other late-stage development pipelines. Others are still in the very early stages of development and have not yet been tested in humans.

Based on evidence from recent studies, the chances of clinical success are low. Of all drugs for infectious diseases that enter Phase 1 testing, just 26.7% go on to obtain approval. Just 31.6% of vaccines that enter Phase 1 testing go on to obtain approval. The size of the development pipeline and interest in COVID-19 may indicate that several of these products will go on to obtain approval, but the safety and efficacy of these products is far from guaranteed. As companies try to bring whatever compounds they have into clinical testing, it’s possible that few, if any, of these products will ultimately prove safe or effective.

Highlights: 95+ 45+ 24+ 40+ Therapeutic medical Vaccines in development Products already approved Products already in clinical products in development for other indications development (6 vaccines, 34 therapies)

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Therapeutic Development

Clinical Company Drug Name Product Type Overview/Highlights History Timeline Sources phase is an L- valine derivative that is an antiretroviral drug from the protease inhibitor class used to Abbott (HIV treat HIV and approval) prevent or treat AIDS. It is often used as a fixed- Abbott received approval AbbVie, dose combination with Approved in 1996 for for the treatment of HIV in Approved Ascletis, another protease HIV. Currently a piece of 1996 under the drug name for another Company Pharmstandard inhibitor, lopinavir. many clinical trials for Ritonavir Therapeutic Norvir. Many trials are indication; announcement , Gilead, Ritonavir is also used in COVID-19 treatments in looking at combinations of in clinical / PubChem Shionogi, combination with combination with other ritonavir and other drugs testing. Toyama sodium drugs. for treatment of COVID-19. Chemical, hydrate, and Janssen, (under the Biogen, Merck trade name Viekira Pak) for treatment of chronic virus genotype 1 infection and cirrhosis of the liver.

The First Affiliated Approved Testing is taking place Hospital of Drug approved for The estimated study for another Reported in in to assess Fujian Medical Fingolimod Therapeutics treatment of multiple completion date is July indication; media / treatment for COVID-19 University sclerosis (Novartis) 1st. in clinical Clinical Trials . testing. Novartis

Previous studies have First Affiliated shown the drug can treat Approved Currently in Phase II. Hospital of Testing taking place in H1N1 lung injury. for another Reported in Estimated study Wenzhou Thalidomide Therapeutic China for treatment of Thalidomide is approved indication; media / completion date is May Medical severe COVID-19 cases. in the US, though has a in clinical 30th. University REMS due to causing birth testing. defects.

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Clinical Company Drug Name Product Type Overview/Highlights History Timeline Sources phase Approved FDA granted approval to for another Reported in Sildenafil Testing in China Currently in Phase III in Tongji Hospital Therapeutic Pfizer under the name indication; media / citrate currently. China. Viagra. in clinical Clinical Trial testing.

Peking Union Medical Approved Currently being tested Reported in College Approved for many for another Cortico- in China and under a Trial estimated to Media / Hospital Therapeutic indications by the FDA indication; steroid phase III clinical trial for complete on April 25th Clinical Trial / including cancers. in clinical H1N1 WHO University of testing Oxford

Novartis subsidiary Sandoz is donating up to 130 million doses of University of generic Minnesota hydroxychloroquine.

Many groups are University of assessing the ability for Some clinical results are Oxford Company Chloroquine to treat already available but Approved announcement Chloroquine patients with Approved by the FDA for are inconclusive. HCQ for another Various / FDA / HHS / / Hydroxy- Therapeutic mild/moderate COVID- treatment of malaria was able to shorten indication; Chinese Reported in chloroquine 19 to reduce the (Novartis). recovery times in one in clinical research media / duration of symptoms study. testing sponsors Clinical Trial and decrease viral

shedding. The FDA issued an EUA Novartis to allow the drug to be

distributed from the Mylan national stockpile and used on hospitalized patients.

Prior FDA approval for Approved Incyte’s Jakofi to treat Tongji Hospital Currently being tested Study in China set to for another Reported in “steroid-refractory acute Ruxolitinib Therapeutic in China for COVID-19 complete by end of indication; media / WHO / GVHD in adult and Incyte Corp. treatment. year in clinical Clinical Trial pediatric patients 12 years testing and older.”

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Clinical Company Drug Name Product Type Overview/Highlights History Timeline Sources phase

Wuhan Infectious Approved Diseases Testing taking place in Merck (Schering) received No timeline. Clinical for another Hospital Peginterfero China. Also studying Reported in Therapeutic approval for the treatment trials currently occurring indication; n alfa-2b the effect in MERS Media / WHO of hepatitis C previously. in China. in clinical Eiger treatment. testing BioPharmaceut ic

A recombinant humanized monoclonal Amgen received prior Approved Clinical trial is currently Reported in Qilu Hospital IgG1 antibody that approval from the FDA for another Therapeutic – recruiting in China. media / of Shandong Bevacizumab binds to and inhibits the under the name Avastin indication; antibodies Report out expected in Clinical Trial / University biologic activity of which is indicated for in clinical April. DrugBank human vascular cancer treatment. testing endothelial growth factor (VEGF). Gilead Clinical trial currently

taking place in China Sichian for COVID-19 Approved Academy of Approved by the FDA in treatment. It works as a for another Medical Emtricitabine Therapeutic - 2004 under name Truvada WHO / Clinical “Non-nucleoside No timeline indication; Sciences & , tenofovir antiviral (Gilead) to treat/prevent Trial in clinical Sichian HIV-1. inhibitor and testing Provincial nucleotide reverse People’s transcriptase inhibitor” Hospital Roche

BARDA Approved by FDA under No timeline, but further Approved Roche is starting a the name than others studying the for another Company First Affiliated Therapeutic – Phase III clinical trial for Actemra/RoActemra Tocilizumab same drug in other indication; announcement Hospital of the antibodies treatment of COVID-19 previously, for the countries. Currently in in clinical / Clinical Trial University pneumonia. indication of rheumatoid Phase III testing of Science and artritis. Technology of China

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Clinical Company Drug Name Product Type Overview/Highlights History Timeline Sources phase The company already markets iNO as INOmax in the US to treat term and The company is near-term newborns exploring inhaled nitric suffering from hypoxic Currently working with oxide (iNO) as a respiratory failure caused FDA and other Approved Company Inhaled nitric supportive measure for Mallinckrodt Therapeutic by pulmonary regulatory agencies to for another announcement oxide (ino) COVID-19, particularly hypertension. Additionally, explore the treatment indication. / PubChem for patients with iNO was used in a study to possibility. pulmonary treat six SARS-CoV patients complications. and showed improvements compared to controls. was originally developed by Shionogi Co. and Roche for A and Previously approved influenza B infections. The under another Baloxavir is an inhibitor drug was initially approved indication. Currently in Approved of the influenza cap- for use in Japan in Reported in clinical testing in China for another Baloxavir dependent February 2018. It was media / Roche Therapeutic in combination with indication; marboxil endonuclease approved by the FDA on PubChem / at The First in clinical and is used as therapy October 24, 2018, for the Clinical Trials Affiliated Hospital, testing of influenza A and B. treatment of acute Zhejiang University uncomplicated influenza in School of Medicine. patients 12 years of age or older who have been symptomatic for no more than 48 hours. -beta is a form of recombinant A clinical trial is BIOGEN received approval human interferon used ongoing in France, Approved in the US for this drug to Company to slow disease sponsored by the for another Interferon treat multiple sclerosis. A announceme Merck KGaA Therapeutic progression and reduce French Institut National indication; beta-1a trial for COVID treatment nt / DrugBank the frequency of clinical de la Sante et de la in clinical began in France in early / Clinical Trial symptoms in patients Recherche Medicale testing. March. who have relapsing (INSERM). multiple sclerosis.

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Clinical Company Drug Name Product Type Overview/Highlights History Timeline Sources phase Baricitinib is a selective and reversible Janus kinase 1 (JAK1) and 2 (JAK2) inhibitor. Janus kinases belong to the Eli Lilly received approval tyrosine protein kinase in 2018 to treat arthritis family and play an under the brand name important role in the Olumiant. Baricitinib was proinflammatory also approved in the EU in pathway signaling that February 2017 as a Approved in the US and Approved Reported in is frequently over- second-line orally Eli Lilly Baricitinib Therapeutic EU in 2018 under for another media / activated in administered treatment for separate indication. indication. PubChem autoimmune disorders moderate to severe active such as rheumatoid rheumatoid arthritis in arthritis. By blocking the adults, either as a actions of JAK1/2, monotherapy or when baricitinib disrupts the combined with activation of methotrexate. downstream signaling molecules and proinflammatory mediators. Chloroquine is a 4- aminoquinoline with antimalarial, anti- inflammatory, and potential Chloroquine is an chemosensitization and aminoquinolone derivative radiosensitization first developed in the activities. Although the 1940s for the treatment of mechanism is not well malaria. Chloroquine was understood, granted FDA approval on Approved in 1949 Approved Reported in Sanofi Chloroquine Therapeutic chloroquine is shown to October 31, 1949. Sanofi under separate for another media / inhibit the parasitic received this approval indication. indication. DrugBank enzyme heme under the product name polymerase that Aralen. Since then, other converts the toxic heme companies have also had into non-toxic NDAs or ANDAs approved hemazoin, thereby for this drug. resulting in the accumulation of toxic heme within the parasite.

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Clinical Company Drug Name Product Type Overview/Highlights History Timeline Sources phase J&J received approval in 2006 for treatment of HIV Approved in 2006 under the name Prezista. under separate Johnson & is an With the recent SARS-CoV- indication. Clinical trials Johnson (HIV) antiretroviral protease 2 outbreak of 2019 that started in 2020 for inhibitor that is used in causes coronavirus Approved treatment of Company Gilead (testing the treatment of human disease, darunavir is being for another Coronavirus, which are Announcemen for COVID-19), Darunavir Therapeutic immunodeficiency virus studied as a possible indication; set to conclude in t / Nature / (HIV) and prevention of treatment for SARS-CoV-2 in clinical August. J&J has Clinical Trial Janssen acquired due to in vitro evidence testing. indicated there is a lack (testing for immunodeficiency supporting its ability to of evidence supporting COVID-19) syndrome (AIDS). combat this infection. darunavir as a COVID- Clinical trials are underway 19 treatment. and are expected to conclude in August 2020. Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors The University of are used for a similar Minnesota is enrolling Approved Losartan was granted FDA Reported in indication but are for clinical trials to see if for another University of approval in 1995, and media / Losartan Therapeutic associated with a losartan can reduce indication; Minnesota many companies offer DrugBank / cough. When patients organ failure in COVID in clinical generic versions. Clinical Trial with ACE inhibitor patients, and avoid testing. associated coughs are hospitalizations. switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Sargramostim is a human recombinant Partner Therapeutics granulocyte has announced the start colony- of a clinical trial at Approved Company Berlex Labs has already Sargramosti stimulating factor (GM- University Hospital for another announceme Partner received FDA approval for m, rhu-GM- Therapeutic CSF) expressed in yeast. Ghent. The company indication; nt / DrugBank Therapeutics this drug under the name CSF It is a that notes medical centers in clinical / Clinical Leukine. is 127 residues. in other countries are testing. Trials Substitution of Leu23 also considering joining leads to a difference the trial. from native protein.

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Clinical Company Drug Name Product Type Overview/Highlights History Timeline Sources phase is an antiviral inhibitor used for the treatment and prophylaxis of infection Oseltamivir was approved with influenza viruses A by the FDA in 2012 for the Trials are ongoing in (including pandemic treatment of influenza. China in combination Approved H1N1) and B. Company Roche received this and comparison to for another Oseltamivir exerts its announceme Tongji Hospital Oseltamivir Therapeutic approval under the name other antiviral therapies. indication; antiviral activity by nt/ DrugBank Tamiflu. Roche has stated The trial is expected to in clinical inhibiting the activity of / Clinical Trial that it is extremely unlikely be completed by July 1, testing. the viral neuraminidase that this would be effective 2020. enzyme found on the to treat the virus. surface of the virus, which prevents budding from the host cell, viral replication, and infectivity. Anakinra is a recombinant, nonglycosylated human Approved interleukin-1 receptor Swedish A trial is ongoing and for another DrugBank / Anakinra and antagonist (IL-1Ra). Both drugs are approved Orphan Therapeutic set to complete in indication; DrugBank / emapalumab Emapalumab, also by the FDA. Biovitrum September. in clinical Clinical Trials known as NI-0501, is a testing. fully human monoclonal antibody that targets interferon gamma. The company announced they are starting a clinical Sargramostim is a trial for sargramostim for Approved human recombinant treatment of patients with The trial is taking place for another Company Partner Sargramo- granulocyte Therapeutic COVID-19 related currently at University indication; announceme Therapeutics stim macrophage colony- respiratory illness. The Hospital Ghent. in clinical nt / DrugBank stimulating factor (GM- drug (known as Leukine) is testing. CSF) expressed in yeast. already approved by FDA for five other conditions.

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Clinical Company Drug Name Product Type Overview/Highlights History Timeline Sources phase Lopinavir is an anti- Abbott Laboratories Approved in 2000 in retroviral protease received approval in 2000 combination with inhibitor used in to treat HIV using the ritonavir to treat HIV. Abbott (HIV combination with other combination of lopinavir Currently under Company approval) antiretrovirals in the and ritonavir under the investigation in Approved announceme treatment of HIV-1 brand name Kaletra. Lopinavir Therapeutic combination with for another nt / DrugBank AbbVie infection. Lopinavir is Lopinavir is currently under ritonavir for the indication. / Clinical (investigating marketed and investigation in treatment of COVID-19. results for COVID-19) administered combination with ritonavir One study has shown exclusively in for the treatment of no clinical benefit from combination with COVID-19 caused by the treatment. ritonavir. SARS-CoV-2. is a synthetic benzamide with antiprotozoal activity. Nitazoxanide Romark Pharmaceuticals exerts its antiprotozoal received approval in 2005 activity by interfering to treat parasitic infections with the under the drug name pyruvate ferredoxin/ Alinia. Recently, this drug Approved in 2005 for Approved Reported in flavodoxin Romark Nitazoxanide Therapeutic has been studied as a treatment of parasitic for another media / broad-spectrum antiviral infections. indication. DrugBank dependent electron agent due to its ability to transfer reaction, which inhibit the replication of is essential to anaerobic several RNA and DNA energy metabolism. viruses. PFOR enzyme reduces nitazoxanide, thereby impairing the energy metabolism. Siltuximab prevents the Janssen received FDA A case-control study is binding of IL-6 to EUSA Pharma approval for siltuximab in ongoing. One third of soluble and membrane- Approved Company 2014 under the name patients observed in an Siltuximab Therapeutic bound IL-6 receptors by for another announceme Papa Giovanni Sylvant for the treatment of interim analysis showed forming high affinity indication. nt / DrugBank XXIII Hospital multicentric Castleman’s clinical improvement, complexes with human disease. and 43% were stable. interleukin-6 (IL-6).

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Clinical Company Drug Name Product Type Overview/Highlights History Timeline Sources phase Penciclovir is a synthetic acyclic guanine derivative with antiviral activity, mainly used to treat infections from virus (HSV) types 1 and 2. In HSV infected cells, penciclovir is phosphorylated by viral thymidine kinase and subsequently Mylan received approval in Approved Reported in converted by cellular Approved in 1996 for Mylan Penciclovir Therapeutic 1996 to treat HSV under for another media / kinases into the active HSV. drug name Denavir. indication. PubChem metabolite, penciclovir triphosphate, which competitively inhibits viral HSV polymerase by blocking deoxyguanosine triphosphate substrate binding. As a result, herpes viral DNA synthesis and replication are selectively inhibited. is a synthetic nucleoside analog Valeant Pharmaceuticals of ribofuranose with received approval in 1985 Two approvals for activity against hepatitis for treatment of respiratory separate indications by C virus (HCV) and other Valeant infections in separate companies RNA viruses. Ribavirin is Approved Reported in (Bausch) children/babies under the were received decades Ribavirin Therapeutic incorporated into viral for another media / name Virazole. Later, ago. These targeted RNA, thereby inhibiting indication. PubChem Merck Merck received approval specific populations for viral RNA synthesis, to treat HCV with this drug HCV and respiratory inducing viral genome in combination with illness. mutations and interferon alpha 2-b. inhibiting normal viral replication.

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Clinical Company Drug Name Product Type Overview/Highlights History Timeline Sources phase Plasminogen activators are a heterogeneous group of proteolytic MIT and the University that convert of Colorado are MIT Plasminogen to working with hospitals Tissue Various forms of tPA are Company Fibrinolysin. They are in Massachusetts and Approved plasminogen already approved, for announcement University of Therapeutic concentrated in the Colorado to begin for another activator example Genentech’s / DrugBank / Colorado at lysosomes of most cells clinical testing in the US. indication. (tPA) Alteplase. China results Denver and in the vascular Some results from endothelium, China show positive particularly in the response to the drug. vessels of the microcirculation. Eculizumab is a monoclonal antibody Alexion has discussed that targets with various complement protein Alexion received FDA government agencies C5. Binding to this approval for this drug in that they believe Approved Company protein prevents the 2007 for the treatment of eculizumab should be Alexion Eculizumab Therapeutic for another announcement activation of a paroxysmal nocturnal investigated and indication. / DrugBank complement terminal hemoglobinuria to reduce considered for complex, which is used hemolysis. treatment of COVID, to treat a number of but nothing more has autoimmune happened thus far. conditions. Favipiravir is a pyrazinecarboxamide derivative with activity Discovered by Toyama against RNA viruses. Chemical Co., Ltd., in Favipiravir is converted Previously approved in Reported in Japan, favipiravir is a to the ribofuranosyltri- Japan. Clinical trial in In clinical media / Fujifilm Favipiravir Therapeutic modified pyrazine analog phosphate derivative by China has shown testing. DrugBank / that was initially approved host enzymes and positive results. Clinical Trial for therapeutic use in selectively inhibits the resistant cases of influenza. influenza viral RNA- dependent RNA polymerase.

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Clinical Company Drug Name Product Type Overview/Highlights History Timeline Sources phase is an orally bioavailable non- nucleoside inhibitor of the polymerase basic protein 2 (PB2) subunit of the polymerase complex with potential antiviral Pimodivir is under activity. Upon Extensive testing has Reported in Johnson & investigation in clinical trial In clinical Pimodivir Therapeutic administration, been done already for media / Johnson NCT02658825 by Johnson testing. pimodivir occupies the influenza. PubChem & Johnson. 7-methyl GTP (m7GTP) of PB2, thereby blocking the cap-snatching activity of the influenza polymerase complex and inhibiting the synthesis of viral mRNA. In 2017, its activity against the coronavirus family of , or GS-5734, viruses was also is an adenosine demonstrated. Remdesivir Not yet approved. triphosphate analog is also being researched as Previous tests had taken first described in the Company a potential treatment to place for Ebola. Current literature in 2016 as a announcement Gilead SARS-CoV2, the tests are taking place in In clinical Remdesivir Therapeutic potential treatment for / DrugBank / Sciences coronavirus responsible tandem in the US and testing. Ebola. Gilead recently Clinical Trial / for COVID-19. Gilead China for COVID-19. received orphan drug FDA Sciences performed the Report out from trial status from FDA, but testing to treat Ebola and expected in April. voluntarily rescinded it is in Phase III clinical trials after backlash. in the US and China for COVID-19. It has been in use in Russia is currently Umifenovir is an - for approximately 25 years being investigated as a based, hydrophobic, and in China since 2006. potential treatment and dual-acting direct Umifenovir's ability to exert prophylactic agent for Reported in antiviral/host-targeting antiviral effects through COVID-19 caused by In clinical media / Pharmstandard Umifenovir Therapeutic agent used for the multiple pathways has SARS-CoV2 infections in testing. PubChem / treatment and resulted in considerable combination with both Clinical Trial prophylaxis of influenza investigation into its use currently available and and other respiratory for a variety of enveloped investigational HIV infections. and non-enveloped RNA therapies. and DNA viruses. Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Clinical Company Drug Name Product Type Overview/Highlights History Timeline Sources phase Beijing BDB-1 received approval BDB-1 works as an anti- Clinical trials should Defengrei in February to move In clinical Reported in BDB-1 Therapeutic C5a monoclonal have already began in Biotechnology, forward on clinical trials in testing. media antibody. China. Co China for COVID-19. The companies press release states, "Brilacidin is one of the few drugs targeting COVID-19 that has been tested in human Testing is scheduled to Brilacidin is Innovation trials for other clinical start the week of March Pharmaceuticals' top indications, providing an Innovation 16, 2020. A company Company defensin mimetic drug established safety and In clinical Pharmaceutic- Brilacidin Therapeutic announcement notes announcement candidate, which will be efficacy profile, thereby testing. als, Inc. that they received data / PubChem tested against SARS- potentially enabling it to supporting Brilacidin’s CoV-2. rapidly help address the inhibition of the virus. emerging worldwide coronavirus crisis, developed both as an intravenous medicine and as a vaccine." Wuhan Hamilton Biotechnology is Umbilical Wuhan investigating "human cord-derived Clinical trials should Reported in Hamilton umbilical cord-derived Clinical trial was planned in In clinical mesenchyma Therapeutic have already begun in media / Biotechnology, mesenchymal stem cells China in February 2020. testing. l stem cells China. Clinical Trial Co., Ltd. for the potential (intravenous) intravenous treatment" of COVID-19. Ebastine is under Ebastine, investigation for the Wuhan Red lopinavir, Therapeutic - Clinical trial currently treatment of IBS. Lopinavir Primary trial to In clinical Clinical Trial / Cross Hospital interferon antiviral occurring in China. is a popular compound conclude March 31st testing DrugBank alpha among COVID-19 drug development programs. Multiple hospitals are Numerous participating in the trial. Aiming to treat Read out on March 31st, Reported in Chinese Mesenchyma One outcome noted from In clinical Therapeutic pneumonitis caused by currently in Phase II in Media / research l stems cells the treatment is improved testing COVID-19 pneumonia. China Clinical Trial groups respiratory system function recovery time.

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Clinical Company Drug Name Product Type Overview/Highlights History Timeline Sources phase A family of heat-stable, polypeptide hormones secreted by the thymus gland. Their biological activities include Reported in Southeast Thymosin; lymphocytopoiesis, Phase II trial is Therapeutic – Has been previously In clinical media / University in camrelizu- restoration of scheduled to finish April antibodies studied to treat Sepsis. testing. Clinical Trials / China mab immunological 30th PubChem competence and enhancement of expression of T-cell characteristics and function. Leronlimab is a CCR5 Leronlimab is already antagonist intended to being administered Therapeutic – treat patients with though an emergency IND. No timeline, but actively In clinical Company CytoDyn Leronlimab antibodies respiratory Five patients have already treating US patients. testing announcement complications from been treated in New York COVID-19. City. The Frist Affiliated Recombinant protein Novaferon, Reported in Hospital of produced by DNA- Already licensed in China Studies currently taking In clinical Nova, Therapeutic media / WHO / Zhejiang shuffling for . place in China testing interferon Clinical Trial University of IFN-α . Medical School University of British APN01 is a recombinant Previous Phase I and Phase Columbia human angiotensin- Trials are starting in In clinical Company APN01 Therapeutics II clinical trials had positive converting enzyme2 China. testing. announcement results. Apeiron (rhACE1). Biologics This works as a fixed- Ritonavir received dose combination of approval under name In the US, a timeline is Company two HIV-1 protease Noravir for treatment of unclear. The clinical trial Ascletis ASC-09 + In clinical announcement Therapeutic inhibitors, ASC-09 and HIV (Abbott) in 1996. in China has concluded, Pharma, Inc. ritonavir testing. / PubChem / ritonavir, in order to Testing this year in China but no results have Clinical Trials treat HIV and COVID- was seen favorably as a been posted. 19. COVID-19 treatment

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Clinical Company Drug Name Product Type Overview/Highlights History Timeline Sources phase Sarilumab is a fully Sarilumab was developed Press release from the human anti-IL-6R by Sanofi and Regeneron companies states that monoclonal IgG1 Pharmaceuticals, Inc. It was Phase 2/3 trials will be Sanofi antibody that binds to US FDA-approved in May enrolling patients Company both membrane bound 2017 and followed by EU immediately, starting in In clinical announcement Regeneron Sarilumab Therapeutic and soluble interleukin approval in June 2017 for New York. On March testing. / DrugBank / Pharmaceutic- 6 (IL-6) receptor forms, the treatment of moderate 30th it was announced Clinical Trial als thus blocking the cis- to severe rheumatoid that the first patient and trans-inflammatory arthritis (RA) in (outside the US) had signaling cascades of IL- combination with been treated in the trial. 6. methotrexate. Convalescent plasma New York State DOH has The study recently New York State could shorten the begun recruiting Convalesc- began, and will only be In clinical Reported in Department of Therapeutic duration of incubation recovered patients to ent serum for those in “serious testing media Health and lower viral loads of donate plasma for the condition.” COVID. study.

Azvudine is being This drug is not approved Zhengzhou tested at a COVID The clinical trial in China Reported in in the US, but has been In clinical Granlen Azvudine Therapeutic treatment in China, it is was initiated in media / tested for treatment testing PharmaTech an experimental reverse February. Clinical Trial against HIV/AIDS. transcriptase inhibitor.

The drug is already approved in Japan under A clinical trial Camostat mesylate is a Reported by University of Camostat the name Foipan for sponsored by the In clinical Therapeutic serine protease media / Aarhus Mesylate treatment of remission of University is set to testing inhibitor. Clinical Trial acute pancreatitis being March 31st. symptoms. The two companies On April 2nd the want to expand the use company announced Sorrento of Celularity's CYNK- The NK cells have already they received FDA Therapeutics Therapeutic - 001, "an allogeneic, off- been shown to be effective In clinical Company CYNK-001 clearance for their IND cell therapy the-shelf, placental- in treating virally effective testing announcement application and will Celularity derived natural killer cells. start Phase I/II studies (NK) cell therapy" to for COVID. treat COVID-19.

A study has already begun Meplazumab is a The estimated study Tang-Du recruiting in China to see In clinical Meplazumab Therapeutic humanized anti-CD147 completion date is Clinical trial Hospital the effects on pneumonia testing. antibody. December 31st. from COVID.

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Clinical Company Drug Name Product Type Overview/Highlights History Timeline Sources phase Lenzilumab “neutralizes The company is moving granulocyte towards Phase III trials macrophage colony Humanigen is testing this for COVID related In clinical Company Humanigen Lenzilumab Therapeutic stimulating factor (GM- drug for multiple complications. The FDA testing. announcement CSF) a key cytokine in indications. has authorized the initiation of cytokine compassionate use in storm.” this case.

Interferon beta is widely The company Company SNG001 is an inhaled used for other indications, announced it treated its In clinical Synairgen SNG001 Therapeutic version of interferon announcement but this inhalable version is first COVID patient on testing. beta-1a. / DrugBank not yet approved for use. March 31st.

Plitidepsin is a peptide found in tunicates which shows promise in On March 24th the shrinking tumors in company submitted a pancreatic, stomach, The drug is approved in Phase II clinical trial Company bladder, and prostate In clinical PharmaMar Plitidepsin Therapeutic Australia for the treatment protocol to the Spanish announcement cancers. The specific testing of multiple myeloma. Medicines and / DrugBank marine organism is Healthcare Products Aplidium albicans. It is Agency. also of interest as a potential treatment for some leukemias. The TAK-888 antibody is a plasma-derived anti-SARS-CoV-2 A spokesperson said TAK-888 polyclonal the therapy could be (plasma- hyperimmune globulin available to treat high- At the beginning of March, derived anti- (H-Ig). Takeda stated risk patients in 9-18 Takeda started Not yet in Takeda SARS-CoV-2 Therapeutic - they believe they will be months, though it is Company development of TAK-888 clinical Pharmaceutical polyclonal antibody able to progress past unclear whether this announcement to treat high-risk COVID-19 testing. hyperimmun Phase I safety trials due would be in a clinical patients. e globulin to the IgG trial or available under (H-Ig)) immunoglobin and EUA or other therapies previously mechanism. proving to be "clinically safe."

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Clinical Company Drug Name Product Type Overview/Highlights History Timeline Sources phase Emergent Biosolutions is developing two No official timeline, but plasma-derived The company has already next steps are to products for COVID-19. generated a hyperimmune develop the COVID-HIG Not yet in Emergent COVID-HIG, Therapeutic - Company These products will platform, which supports and COVID-EIG using clinical BioSolutions COVID-EIG antibody announcement utilize the immune other FDA-approved plasma from humans testing. response to create products. and horses, protection from the respectively. COVID-19 infection. Created a multi-year partnership to utilize Both companies bring the H2L2 Harbour Mice historical expertise into the Nothing announced; platform to generate partnership. Harbour however, the statement Harbour monoclonal monoclonal antibodies BioMed brings their from the two Not yet in Therapeutic - Company BioMed with antibodies targeting COVID-19. antibody generation organizations notes a clinical antibody announcement Mount Sinai (mAbs) This therapy will be technology, while Mount commitment to "fast- testing. used to prevent the Sinai brings translational track innovative spread of COVID-19 by medical research research." inhibiting infection of experience. cells. The PolyTope mAb Therapy will be used to combine "the benefits of using well-defined ImmunoPrecis PolyTope and fully characterized The company started their None stated, but Not yet in Therapeutic - Company e Antibodies mAb monoclonal antibodies research program for this currently in an early clinical

antibody announcement with EVQLV Therapy with the essential need topic in February. research phase. testing. for a multi-targeting strategy," ImmunoPrecise said in a statement.

Regeneron has had prior The CEO has stated that mAbs success in mAbs they will know quickly if Regeneron aims to generated development for Ebola the mAbs are safe and Regeneron discover and develop a Not yet in against Therapeutic - and MERS. They currently effective, further noting Company Pharmaceutic- mAbs that are effective clinical SARS-CoV-2 antibody note having 1,000 if this is the case, the announcement als in both preventing and testing. spike on antibodies in dishes being company could begin treating COVID-19. pseudovirus screened and selected for mass production in the their COVID-19 efforts. late summer of 2020.

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Clinical Company Drug Name Product Type Overview/Highlights History Timeline Sources phase

No stated timeline. The mAbs from partnership between Vir patients Vir and WuXi want to Vir already discovered the groups includes Not yet in Biotechnology recovered Therapeutic - use human monoclonal multiple monoclonal clinical development, Company clinical from SARS or antibody antibodies to treat antibodies that can attach manufacturing and announcement testing. WuXi Biologics another COVID-19. to COVID-19. commercialization, coronavirus which will begin at a later time.

Very few details have The company started been released, the Anti-SARS- preparations to test The group began Not yet in Therapeutic - program wants to use Company NanoViricides CoV-2 candidates in cell cultures preparation to test clinical nanoparticle the companies announcement program against coronaviruses patients in January. testing. nanovericide using the ACE2 receptor. technology. Immunother The company statement LEAPS peptides have been apy notes this tested against H1N1 in None, development Not yet in CEL-SCI treatment Therapeutic - immunotherapy could partnership with NIAID and Company efforts were initiated on clinical Corporation using LEAPS peptide reduce COVID-19 viral were shown to reduce announcement March 9th. testing. peptide load and tissue damage morbidity and mortality in technology due to lung infection. mice. Testing and The announcement made The company plans to None, but the company publishing Feb 6th noted Insolico will Therapeutic - examine multiple Small will continually post Not yet in Insilico structures of publish structures of small Company small molecules that can updates to their site. It clinical Medicine up to 100 molecules targeting key announcement molecule target COVID-19 has so far posted 6 testing. small protein and synthesize and protein. small molecules. molecules test up to 100 molecules.

Research is taking place The company has None, but company in the US and China to previously used siRNA considers itself "well Developing Not yet in Therapeutic - develop RNA drugs for treatment of positioned" to make an Company Sirnaomics novel siRNA clinical siRNA interference (RNAi)- SARS and H5N1 in impact particularly announcement therapy testing. based prophylactics addition to other viral among patients with and therapeutics. respiratory infections. unmet medical need.

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Clinical Company Drug Name Product Type Overview/Highlights History Timeline Sources phase The two groups have Utilizing Alnylam's already been in At beginning of March "advances in lung partnership for infectious the two groups Vir delivery of novel SARS-CoV-2 disease treatments and expanded a deal made Biotechnology conjugates of siRNA" targeting announced on March 4th in 2017 to develop Not yet in Therapeutic - with Vir's additional Company human that they are now RNAi programs for clinical Alnylam siRNA capabilities, the announcement monoclonal expanding their infectious diseases to testing. Pharmaceutic- partnership will try to antibodies partnership (and their include siRNA als create siRNAs to treat technologies on the side of therapeutics for COVID- COVID-19 and other Vir) to help develop a 19. coronaviruses. COVID-19 treatment. Llama- derived single Flanders domain The group will target Institute for antibodies the SARS-Cov and The group has a second None stated, but the Biotechnology generated Not yet in Therapeutic - SARS-CoV-2 spike pending program using VHH candidate has Reported in (VIB) against spike clinical

antibody protein using Llama- VHH-generated against already been media protein testing. derived single domain SARS-CoV-2. generated. Ghent domain antibodies (VHHs). University conserved across SARS- CoV and Sars-COV-2 The agreement between the companies was announced on the March No discussed timeline, Eli Lilly entered into an 12, 2020. Previously, however AbCellera agreement with AbCellera was awarded a technology aims to Eli Lilly Not yet in Unknown Therapeutic- AbCellera Biologics to contract from DoD DARPA "quickly screen for Company clinical antibody antibody develop an to create an end-to-end potent antibodies and announcement AbCellera testing. experimental therapy platform for rapid validate potential for COVID-19. pandemic response in candidates on tight 2018. This tech was tested timelines." at the time against MERS- CoV with positive results.

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Clinical Company Drug Name Product Type Overview/Highlights History Timeline Sources phase AbbVie will evaluate Company previously HIV medicine received approval for the Kaletra/Aluvia for drugs for the treatment of Previously approved in COVID-19 treatment in HIV. AbbVie donated 2005 and Not yet in Company Lopinavir/ partnership with health AbbVie Therapeutic Aluvia to China in January announcement for new clinical announcement ritonavir authorities and for experimental use exploration came March testing. / PubChem institutions to examine against COVID-19, and 11, 2020. efficacy and antiviral Chinese media reports activity in the have said it is effective. . Rintatolimod is a synthetic derivative of inosinic acid with antiretroviral and immunomodulatory properties. Atvogen Aim acts through a number Immunotech of pathways to stimulate Inc. (formerly intracellular antiviral Hemispherx activity of the immune Approved for chronic Biopharma March 9, 2020 press system: it stimulates fatigue syndrome in Not yet in Company Inc.) release indicated Rintatolimod Therapeutic interferon production; various countries; entered clinical announcement testing would soon activates discovery for coronavirus testing. / PubChem GP Pharm SA begin in Japan. the oligoadenylate synt in February 2020.

hase-RNase L pathway; Goethe stimulates natural killer University cell activity; and acts as Frankfurt a non-mitogenic stimulator of the immune system. This agent also inhibits replication of HIV in vitro. Novel Developing product for None stated, but Beroni Beroni Group Beroni Group has medication both detection and has discussed working Not yet in previously worked on Company using Therapeutic treatment of COVID-19 with regulatory bodies clinical Tianjin products for global announcement nanobody using nanobody-based to advance toward testing. University diseases. technologies technology. clinical trials.

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Clinical Company Drug Name Product Type Overview/Highlights History Timeline Sources phase Creating a monoclonal Antibodies antibody for treatment Celltrion has already from and prevention of sourced a library of Clinical testing set to Not yet in Therapeutic – Company Celltrion recovered COVID-19. They have antibodies from blood of begin in the third clinical antibody announcement COVID-19 been selected by the recovered patients in quarter of 2020. testing. patients Korea CDC as a Korea. preferred developer. Antibodies Kamada is looking to Kamada specifically from develop a polyclonal The company will use their notes “there can be no Not yet in Therapeutic – Company Kamada recovered immunoglobulin proprietary plasma derived assurance” for timely, clinical antibody announcement COVID-19 treatment for serious IgG platform. safe, and effective testing patients COVID-19 cases. therapy development. Pluristem Therapeutics The groups are working BIH Center for in collaboration to Plutistem has requested to Not yet in Regenerative PLX cell examine effects of PLX utilize a per-patient Working to use in per- Company Therapeutic clinical Therapy product cell product candidates compassionate use patient treatment. announcement testing. for COVID-19 framework in Israel. Berlin Center complications. for Advanced Therapies Scientists at the Erasmus MC No timeline, the Human University discovered Not yet in Therapeutic – The antibody has not been scientists are looking for Announcemen monoclonal an antibody they clinical Utrecht antibodies tested on humans. a pharmaceutical t antibody believe can detect and testing University company partner. prevent COVID-19. Using proprietary Have engaged with WHO antibody discovering No timeline, hope to Not yet in Monoclonal Therapeutic – and European Federation Company AstraZeneca tech to search for progress to clinical trial clinical antibodies antibodies of Pharmaceutical announcement antibodies to fight evaluation testing. Industries. COVID-19. The company is evaluating its allogeneic No timeline. Company mesenchymal stem cell is currently talking with Prior studies of this Not yet in Remestemce product for treatment of various stakeholders in Company Mesoblast Therapeutic product against COPD clinical l-L patients with acute US, Australia, China and announcement have been positive. testing. respiratory distress Europe to advance symdrome from COVID- forward. 19.

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Clinical Company Drug Name Product Type Overview/Highlights History Timeline Sources phase The company is OT-101, a operating a rapid OT-101 is also being Not yet in Mateon Currently in preclinical Company TGF-Beta Therapeutic antiviral response investigated for anti-cancer clinical Therapeutics testing. announcement antisense program against purposes. testing. coronaviruses. Partnering with Dr. Prior studies note that this No timeline, Not yet in BXT-25; David Platt to develop a treatment could help Company Bioxytran Therapeutics partnership was clinical glycoprotein galectin inhibitor that “restore the adaptive announcement announced March 24th testing. could treat COVID-19. immune system.” Ifenprodil is an “NDMA receptor glutamate receptor antagonist specifically targeting Algernon is a company Algernon is submitting the NMDA-type subunit focused on drug re- ethics approval for a Algernon Not yet in Ifenprodil, 2B (Glu2NB). Ifenprodil purposing. This drug is phase II clinical trial in Company Pharmaceutic- Therapeutic clinical NP-120 also exhibits agonist currently approved in Australia, and has filed announcement als testing. activity for the Sigma-1 South Korea and Japan, a pre-IND meeting receptor, a chaperone developed by Sanofi. request with FDA. protein up-regulated during endoplasmic reticulum stress.” Nafamostat is a synthetic serine protease inhibitor that is commonly formulated Nafamostat mesylate is The University of Tokyo with hydrochloric acid currently approved in announced they intend Not yet in Company University of due to its basic Nafamostat Therapeutic Japan under the brand to launch clinical trials in clinical announcement Tokyo properties. It has been name Fusan for treatment April for the treatment testing. / DrugBank used in trials studying of acute pancreatitis. of COVID-19. the prevention of Liver Transplantation and Postreperfusion Syndrome. Vicromax is an orally administered, broad Vicromax previously BioSig will develop this Not yet in BioSig spectrum anti-viral completed phase I and II drug under ViralClear Company Vicromax Therapeutic clinical Technologies agent. BioSig recently clinical trials for other Pharmaceuticals, one of announcement testing aquired the right to indications. their subsidiaries. develop it.

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Clinical Company Drug Name Product Type Overview/Highlights History Timeline Sources phase

Galidesivir is an adenosine analogue that has been investigated for use against . While testing has been In animal studies, BioCryst developed this done previously against was effective drug and Phase 1 clinical some infectious in increasing the trials have begun to diseases, no approvals survival rates from determine the safety of this have been received. infections caused by drug in humans for Because it has already Not yet in Company various pathogens, BioCryst Galidesivir Therapeutic treatment of yellow undergone Phase 1 clinical announcement including Ebola, fever. Because of its testing in humans and testing. / DrugBank Marburg, Yellow Fever activity against other was reportedly “well and Zika viruses. In coronaviruses, it may be tolerated,” it may be vitro, it displayed studied as a potential able to enter clinical broad-spectrum therapy for COVID-19. testing for COVID-19 at antiviral activity against an accelerated rate. various negative- and positive-sense RNA viruses, including coronaviruses, filoviruses, and arenaviruses. AlloVir will use proprietary technology AlloVir has already done to develop a CoV other work in this space, AlloVir therapy that may be T-cell and has announced they Not yet in used alone, or in No timeline has been Company therapy, Therapeutic will expand their current clinical Baylor College combination with the discussed. announcement ALVR106 partnership with Baylor in testing of Medicine companies multi- order to progress against respiratory COVID. investigational therapy (ALVR106). The company announced they are working to create a Distributed Bio say they COVID treatment using have already generated a Not yet in Company Distributed Bio Antibody Therapeutic their Distributed Bio panel of therapeutic No timeline discussed. clinical announcement SuperHuman 2.0 antibodies to potentially testing technology, as well as a neutralize the virus. platform called Tumbler.

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Clinical Company Drug Name Product Type Overview/Highlights History Timeline Sources phase CoCrystal Pharma The two groups have No timeline has been formed a partnership to They will use their Novel discussed but they are Not yet in Kansas State develop antiviral proprietary drug discovery Company antiviral Therapeutic working quickly toward clinical University treatments for norovirus platform to develop a announcement therapeutic pre-clinical testing Research and coronavirus novel antiviral. development. Foundation infections. (KSURF) The company has been The group is working WP1122 works by working on WP1122, their with a “major Texas Not yet in limiting the ability of a Company Moleculin WP1122 Therapeutic antiviral, for a while. With University” on this. They clinical virus (like COVID-19) to announcement the rise of COVID, there hope to generate testing. replicate. was greater urgency. animal data soon. The therapy is a recombinant anti- COVID hyperimmune gammaglobulin and works by reproducing The company is Gigagen has partnered Not yet in whole anti-body currently recruiting Company GigaGen rCIG Therapeutic with Access Biologics for clinical repertoires of recovered patients to announcement manufacturing. testing recovered patients and donate blood. will aim to provide passive immunity to help recover and fight the infection. They combination Vir Biotech is working No timeline has been approach being taken across multiple fronts to Generation Bio Gene stated, but the press Not yet in could neutralize use its technology to Company therapy/ Therapeutic announcement notes clinical antibodies and provide create a COVID treatment. announcement Vir Biotech mAbs they are beginning testing protection from the Generation Bio is a genetic research. virus. medicines company. Both groups are Neutralizing antibodies collaborating to utilize No timeline stated, the Amgen defend healthy cells by Adaptive Biotech’s companies are working Human interfering with the Not yet in proprietary immune on finalizing their Company Adaptive neutralizing Therapeutic invading viruses clinical medicine platform and partnership and note announcement Biotechnol- antibodies biological function. This testing. Amgen’s expertise across the desire to work ogies could work to treat and various development quickly. prevent the virus. areas.

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Clinical Company Drug Name Product Type Overview/Highlights History Timeline Sources phase Tsinghua Multiple antibodies with University therapeutic potential have been identified The hospital and university The group wants to Human 3rd People’s and the groups, will work to discover move from selection of Not yet in neutralizing Company Hospital of Therapeutic working in tandem, will antibodies, while Brii Bio a lead candidate to first clinical monoclonal announcement Shenzhen advance multiple will provide development human trails in 6 testing antibodies candidates for a expertise. months. Brii prophylactic and Biosciences therapeutic. Vanderbilt University Vanderbilt wants to Medical Center Antibodies identify and analyze Thousands of antibodies The goal is to start Not yet in from antibodies from the that have been identified Company DARPA Therapeutic human trials by the clinical recovered blood of recovered are being analyzed by announcement summer. testing. patients patients to neutralize Vanderbilt. Multiple the virus. additional partners TJM2 is an antibody Not yet in I-Mab that may help treat I-Mab has submitted an Company TJM2 Therapeutic No timeline stated. clinical Biopharma cytokine storm IND to the FDA. announcement testing. associated with COVID. Gimsilumab is a No timeline stated, but monoclonal antibody A Phase I study was the company is that “targets GM-CSF, a completed and showed Not yet in prioritizing COVID Company Roivant Gimsilumab Therapeutic pro-inflammatory favorable safety and clinical studies and postponing announcement cytokine found to be tolerability. COVID-specific testing. Phase II studies for up-regulated in COVID- studies have not started. another indication. 19 patients.” The collaboration will use the proprietary The two groups monoclonal antibody No timeline is Vir announced a platform from Vir, and discussed, but the Not yet in Biotechnology partnership to develop GSK’s expertise. They also Company Antibodies Therapeutic company clinical solutions for plan to use CRISPR announcement announcement notes testing. GSK coronaviruses at-large, screening and artificial the need for efficiency. including COVID-19. intelligence to identify compounds that “target cellular host genes.”

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Clinical Company Drug Name Product Type Overview/Highlights History Timeline Sources phase The development process The company wants to will be in partnership with develop a COVID Green Cross wants to Not yet in Green Cross NK-cell KLEO Pharmaceuticals, Reported in Therapeutic treatment using a begin trials in the clinical Lab Cell treatment using both companies’ media cancer immunotherapy second half of 2020. testing. antibody recruiting – natural killer (NK) cells. molecules. AT-001 is a novel AT-001 is in Phase III for Applied Therapeutics Not yet in Applied Company AT-001 Therapeutic potent Aldose the treatment for diabetic has submitted an IND to clinical Therapeutics announcement Reductase inhibitor. cardiomyopathy. the FDA. testing.

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Vaccine Development

Drug Name/ Product Company Overview/Highlights History Timeline Clinical phase Sources Platform Type First human trials to begin in Seattle at Kaiser Permanente Health Research Moderna creates mRNA vaccines Institute. that use "viral bits" to train the

body to recognize them, rather Moderna has filed an than attenuated viruses. 8-K with the SEC. Company Moderna is a recognized They believe a In Phase 1 announcement industry leader in the Moderna proposed a commercial vaccine clinical testing development of mRNA vaccines, sequence for an is 12-18 months and is Company Status Moderna but many other companies also mRNA vaccine in Vaccine - away, but that progressing Update mRNA use this technology. mid-January 2020. RNA emergency use according to NIAID This shipped for authorization could schedule as of NCT04283461 HHS announced that the drug safety trials at end of make limited use March 23, will transition to BARDA as an February. available by fall 2020. HHS Press “emergency medical product.” 2020. Release BARDA and Moderna are

piloting the preparation of Phase Phase 1 clinical 2 and 3 trials while Phase 1 is testing is expected ongoing with hopes of to conclude June 1, 2020. Estimated study completion date is June 2021.

Company claims its Company Entered clinical CanSino platform has been announcement A recombinant novel coronavirus testing in China on Biologics used to help develop and Vaccine - vaccine (adenovirus Type 5 March 17 and will other vaccines, Development non- vector). The company is continue through In Phase 1 Beijing Ad5-nCoV including one Pipeline replicating classifying its vaccine candidate December 2020. clinical testing. Institute of against Ebola viral vector as globally innovative, but not Biotech- approved by Media globally best-in-class. Estimates the study nology Chinese regulatory will conclude by officials. NCT04313127 December 2022. This government Clinical testing Shenzhen Vaccine – This process will introduce viral Efficient sponsored research began February 15, Geno- artificial proteins and immune Company Site lentiviral institute previously 2020. Estimated In Phase 1 immune antigen modulatory genes to modify vector specialized in CAR-T study completion clinical testing. Medical presenting aAPCs and activate T-cell NCT04299724 system cell therapy date of December Institute cell (aAPC) response. development. 31, 2024.

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Drug Name/ Product Company Overview/Highlights History Timeline Clinical phase Sources Platform Type Netherlands UMC Utrecht NE: Study began on Raboud March 25, 2020 and Bacille Calmette-Guérin (BCG) University is estimated to was developed for tuberculosis Because BCG is a complete December NCT04328441 nearly a century ago. It well-known vaccine Australia: Vaccine – live 25, 2020. (NE) introduces weakened bacteria to for its safety, efficacy In Phase 1 Murdoch BCG vaccine attenuated trigger immune response. The studies against clinical testing. Childrens bacteria AUS: Study began NCT04327206 immune response may be SARS-CoV-2 are key Research on March 30, 2020 (AUS) effective against certain here. Institute and is estimated to respiratory viruses. complete March 30, Royal 2022. Children's Hospital Chemical Institut prevention This would use a pre-exposure In Phase 1 Pasteur with two Study was slated to chemoprophylaxis approach, The timeline for clinical testing. drugs: begin March 30, where health care workers take a approval might be Centre Chemo- 2020 and is potentially effective therapeutic quicker than that of a NCT04328285 Hospitalier prophylaxis Hydroxychlor expected to drug in advance of true biologic Universitaire oquine conclude November seroconversion from the SARS- vaccine. de Saint 30, 2020. CoV-2 virus. Etienne Liponavir/ ritonavir This is one of the few Vaccine – candidates for an Modified Uses a genetically modified Study is set to begin oral vaccine, which bacTRL- bacteria bacterium that expresses the on April 30, 2020 In Phase 1 Symvivo has some benefits NCT04334980 Spike expressing SARS-CoV-2 spike protein to and conclude clinical testing. for distribution and protein trigger an immune response. December 31, 2021. delivery over subunit injection vaccines. Inovio received $5M from the Gates Foundation for research Phase 1 studies DNA plasmid on a smart delivery device Began preclinical began on April 7, Company vaccine dubbed Cellectra 3PSP for use Vaccine - trials and 2020 and are In Phase 1 announcement Inovio Electro- with the INO-4800 COVID-19 DNA preparatory research expected to clinical testing. poration vaccine candidate. This is one of in January. conclude November NCT04336410 device the only companies developing 2020. a vaccine and accompanying medical device.

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Drug Name/ Product Company Overview/Highlights History Timeline Clinical phase Sources Platform Type Expected to go into clinical trials in late spring 2020. Has This technique uses an University of ChAdOX1 Vaccine - ChAdOX1 will use a been assigned NCT adenovirus to deliver genetic Oxford and Matrix-M non- platform originally number: Not yet in Company material into a cell. Novavax has adjuvant replicating developed for NCT04324606. clinical testing. announcement received $4 million from CEPI to Novavax technology. viral vector malaria. develop a vaccine. Estimated completion date is May 2021.

Vaccine - Market ready by late Ad5 S This uses an adenoviral Greffex is one of the non- 2020/early 2021, Not yet in Company Greffex (GREVAX compound without Ad genes first to move to replicating currently testing in clinical testing. announcement platform) and with plasmid packaging. animal testing. viral vector animals.

Protein Sciences, Uncertain of when subsidiary of S protein Vaccine - Sanofi is working on the vaccine The technology is this would be ready Not yet in Company Sanofi (baculovirus Protein and also has projects based on SARS but looking at clinical testing. announcement Pasteur production) subunit therapeutics front. research. accelerated timeline approval. BARDA Janssen notably Company Vaccine - Janssen is in partnership with created an effective Janssen AdVac and announcement non- HHS for this development, using Ebola vaccine and No official timeline Not yet in PER.C6 replicating adjuvanted recombinant plans to explore announced. clinical testing. BARDA technologies HHS Press viral vector technology. existing coronavirus Release information. The four candidates Scaling up Takis will move to production of preclinical animal candidates this Applied testing. The Vaccine - The group designed 4 DNA month to send back Not yet in Company DNA DNA partnership with DNA vaccine candidates. to Takis for efficacy clinical testing. announcement Sciences Takis is the first testing. Anticipates vaccine in Italy to pre-clinical results by Evvivax move to this stage of end of April 2020. development.

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Drug Name/ Product Company Overview/Highlights History Timeline Clinical phase Sources Platform Type

No official timeline announced, but the Plasmids are injected carrying DNA plasmid Vaccine - Zydus is partnered company statement Not yet in Company Zydus Cadila DNA sequences that code for vaccine DNA with XOMA. speaks to the desire clinical testing. announcement the viral antigen. to develop a "speedy solution."

This is a US-Indian partnership Codagenix which will utilize a method that Human trials will Deoptimized The group claimed Vaccine - live uses a weakened form of a virus begin in summer live to be first to move Not yet in Company Serum attenuated to trigger an immune response 2020, aiming to be attenuated from the lab to clinical testing. announcement Institute of virus from the body. Smallpox and market ready by vaccines preclinical trials. India vaccines use this 2022. method of inoculation. This is a US-Chinese partnership, The company where BravoVax will be anticipates human Vaccine - GeoVax responsible for manufacturing GeoVax will use its clinical trials by the Company MVA non- Not yet in and testing. This method uses GV-MVA-VLP vaccine end of 2020. They announcement encoded VLP replicating clinical testing. BravoVax virus like particles to trigger an platform. are preparing now and Update viral vector immune response, rather than for live animal live copies of the virus. efficacy trials. Altimmune noted on This technique uses an February 28, 2020 Vaccine - Adenovirus- adenovirus to deliver genetic that they have non- Clinical testing in Not yet in Company Altimmune based material into a cell. This project finished the design replicating August 2020. clinical testing. announcement NasoVAX builds on technology used in and synthesis of a viral vector NasoVAX flu treatment. vaccine and will take steps to test animals. Vaxart already operates a proprietary oral Not yet in Vaxart is a small biotech vaccine platform None discussed but clinical testing. Vaxart Vaccine - company specializing in oral called VAAST, which the company believe Company non- vaccine development. They plan has had prior oral vaccines will be Oral vaccine Plans to move announcement Emergent replicating to deploy this technology on success with essential in a future into Phase 1 in and Update Biosolutions viral vector COVID-19. Emergent will be influenza. They are vaccination second half of producing the vaccine. now teaming up with campaign. 2020. Emergent for the chemical development.

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Drug Name/ Product Company Overview/Highlights History Timeline Clinical phase Sources Platform Type Awarded an EU Horizon 2020 grant Drosophilia Vaccine - for the COVID-19 S2 insect cell This method uses insect cells to Goal for 12-month Not yet in Company ExpreS2ion protein (SARS-CoV-2) expression develop recombinant proteins. trial timeline. clinical testing. announcement subunit Coronavirus vaccine system VLPs development program. WRAIR Vaccine - S protein vaccines target the Not yet in Reported by S Protein protein spike on the on the virus, which Unknown Unknown clinical testing. media USAMRIID subunit is used to break into cells. Vaccine - protein "Utilizing its patented Trimer- Clover's previous subunit with Clover Tag© technology, Clover has focus has revolved Dynavax Biopharmace produced a S-Trimer subunit around "developing The company notes providing uticals Inc. vaccine that resembles the novel and that Clover could CpG 1018, Not yet in Company S-Trimer native trimeric viral spike via a transformative quickly produce an adjuvant clinical testing. announcement GSK rapid mammalian cell-culture biologic therapies." large amounts of the used in its based expression system." RNA Dynavax recently vaccine. FDA- Dynavax viruses rely on trimerized joined the approved proteins to form the viral spike. partnership Hep-B vaccine GSK is working on COVID-19 GSK is providing its vaccine multiple fronts with XWG-03 adjuvant for Innovax for use with different partners to GSK vaccine with Vaccine – its vaccine candidate. It is hoped find solutions for No formal timeline Not yet in Company AS04 protein that the combination will trigger COVID. Its adjuvant announced. clinical testing. announcement Innovax adjuvant subunit the immune system to respond is sought as a platform to SARS-CoV-2. “booster” for other

vaccine candidates. The company has finished in silico Peptide vaccines are unique in A vaccine candidate Vaccine - analyses and feels a their ability to be especially was created using Not yet in Company Vaxil Bio Peptide protein vaccine candidate targeted and mitigate Vaxil's proprietary clinical testing. announcement subunit has been unintended reactions. VAXHit platform. successfully identified.

The two companies will use EpiVax has identified Plan to send a series Generex Vaccine - li-Key EpiVax’s NuGenerex Immuno- "hotspots" in COVID- of synthetic amino Not yet in Company protein peptide Oncology li-key technology to 19 acid peptides to clinical testing. announcement EpiVax subunit generate a peptide vaccine. sequences. China for testing.

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Drug Name/ Product Company Overview/Highlights History Timeline Clinical phase Sources Platform Type EpiVax will use proprietary in silico tools which showed success with H7N9. While a COVID-19 Vaccine - S protein vaccines target the EpiVax has joined an sample has been Not yet in Company EpiVax S Protein protein spike on the on the virus, which international obtained, no further clinical testing. announcement subunit is used to break into cells. consortium of progress has been developers called announced. eTheRNA and is working on two candidates. This is a culmination Thus far, S protein vaccines target the of many entities University of partnerships have Vaccine - spike on the on the virus, which coming together to Queensland S protein been formalized, Not yet in Company protein is used to break into cells. This work on a vaccine, clamp making way for more clinical testing. announcement subunit would form a molecular clamp primarily under GSK progress on the around the spike. funding obtained by vaccine to begin. CEPI. Baylor, NY Targets spike proteins and Builds on a Blood Center Vaccine - S1 or RBD receptor binding domains, technique originally No announced Not yet in Reported by protein protein exposing neutralizing epitopes used to target MERS timeline. clinical testing. media Fudan subunit which are vulnerable to attack. and SARS. University In partnership with DARPA, iBio built their FastPharming Facility to generate Both companies are rapid delivery of iBio Subunit expediting their Vaccine - medical Company protein, Will use plant-based expressions work. iBio filed four Not yet in protein countermeasures in announcement CC- plant system and virus-like proteins. provisional patent clinical testing. subunit the case of a and Update Pharming produced applications on pandemic. The March 11, 2020. partners have also had previous experience working on MERS. The group will work Tonix from Tonix's Tonix uses a proprietary Pharma Vaccine - proprietary horsepox Partnership was Horsepox horsevirus as a vector to Not yet in Company replicating vaccine platform announced on vector introduce vaccines into the clinical testing. announcement Southern viral vector currently being used February 26, 2020. immune system. Research for a smallpox vaccine.

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Drug Name/ Product Company Overview/Highlights History Timeline Clinical phase Sources Platform Type The group previously Institute Not yet in sequenced the entire Pasteur This uses a weakened measles No formal timelines, clinical testing. genome of COVID- Vaccine - virus as a vector to introduce but company says it Announced Measles 19. With funding Organization University of replicating coding for antigens against a is aiming to tackle new vector from CEPI, IP has Announcement Pittsburgh viral vector specific virus into the immune this as quickly as partnership on joined a consortium system. possible. March 19, with University of Themis 2020. Pittsburgh and Themis. China CDC mRNA vaccines use "viral bits" to The group isolated The vaccine has Tongji Vaccine - train the body to recognize the first new COVID- Not yet in Reported by mRNA been tested on

University RNA them, rather than attenuated 19 strain on January clinical testing. media animals. viruses. 24, 2020. Stermina Development will utilize the company's mRNA vaccines use "viral bits" to STARR tech platform No reported Arcturus Vaccine - train the body to recognize which may produce timeline, partnership Not yet in Company mRNA RNA them, rather than attenuated a vaccine response announced on clinical testing. announcement Duke-NUS viruses. at lower doses than March 4, 2020. traditional mRNA vaccines.

A vaccine candidate Imperial was generated, and The company said Vaccine - This will use self-amplifying RNA Not yet in Company College saRNA animal testing began new methods are RNA to rapidly produce vaccines. clinical testing. announcement London on February 10, much faster. 2020. The company previously announced successful rabies The mRNA vaccines use "viral vaccination results Expects to begin Vaccine - bits" to train the body to Not yet in Company CureVac mRNA and boasts previous clinical testing in RNA recognize them, rather than clinical testing. announcement expertise in mRNA- June 2020. attenuated viruses. based vaccine manufacturing. The EU has pledged €80 million to CureVac.

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Drug Name/ Product Company Overview/Highlights History Timeline Clinical phase Sources Platform Type BioNTech is partnering with Fosun for the China BioNTech mRNA vaccines use "viral bits" to market. Fosun has Clinical testing by Vaccine – train the body to recognize invested $50 million Not yet in Company Pfizer mRNA the end of April RNA them, rather than attenuated with the potential for clinical testing. announcement 2020. viruses. $85 million more. Fosun Builds on existing agreement with Pfizer for flu vaccine.

Heat The gp96 platform Biologics Vaccine – Heat will engineer multiple viral Viral uses “molecular No timeline Not yet in Company protein proteins and deliver them via its antigens recognition” to announced. clinical testing. announcement University of subunit proprietary gp96 platform. target the virus. Miami

FlowVax FlowVax believes its novel Vaccine –T- Flow Pharma does stable dry delivery platform may offer No timeline Not yet in Company Flow Pharma Cell not have previous powder advantages over traditional announced. clinical testing. announcement development history. platform vaccines.

Two Anticipates clinical German platforms: DZIF faculty have Viral vectors use weakened virus testing to be 12-18 Center for Measles vaccines for Ebola Vaccine – as a vector to introduce coding months out, but Not yet in Company Infection vector and and MERS viral vector for antigens against a specific might be clinical testing. announcement Research modified undergoing clinical virus into the immune system. abbreviated due to (DZIF) virus trials. demand. Ankara

No formal timeline The I-Cell platform uses Sorrento generally has been Vaccine – “replication-deficient human Sorrento I-Cell focuses on immuno- announced, but the Not yet in Company Protein erythroleukemia K562 cells Therapeutics platform oncology and pain company anticipates clinical trials. announcement subunit expressing membrane-bound S1 management. clinical trials in mid protein of the SARS-CoV-2 virus.” 2020.

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Drug Name/ Product Company Overview/Highlights History Timeline Clinical phase Sources Platform Type OncoGen has traditionally focused on cancer treatment, Epitope- Targets viral proteins that are Vaccine – including CAR-T. The based unlikely to mutate with a system No timeline Not yet in Media OncoGen viral company has said peptide that can adapt to population announced. clinical testing. announcement peptides Romania currently vaccine characteristics. lacks the resources to produce the proposed vaccine.

Viral vectors use a weakened IAVI specializes in Recombinant virus as a vector to introduce developing vaccine IAVI/Batavia vesicular Vaccine – No timeline Not yet in Company coding for antigens against a candidates for Biosciences stomatitis viral vector announced. clinical trials. announcement specific virus into the immune hemorrhagic fever virus system. viruses.

Entos currently has Uses a plasmid to stimulate brought no drugs to Entos Proteo-lipid antigen production by the Vaccine – market. It focuses on No timeline Not yet in Company Pharmaceuti platform recipient’s own cells. The DNA oncology, announced. clinical trials. announcement cals (Fusogenix) delivery system gets the DNA autoimmune and directly into cells efficiently. anti-aging.

Medicago has little development history This method uses particles and has primarily Vaccine – Expects to initiate Virus-like similar in structure to SARS-CoV- been focused on flu Not yet in Company Medicago Virus-like human trials in particle 2 to trigger immune response to vaccines. The clinical trials. announcement particle summer 2020. protect against the virus. Canadian government is the primary funder. The research was funded by the Israeli Viral vectors use a weakened government and Clinical trials are MIGAL Infectious virus as a vector to introduce Vaccine – adapted a virus expected to begin Not yet in Company Research bronchitis coding for antigens against a Viral vector vaccine for an avian before summer clinical trials. announcement Institute virus specific virus into the immune condition. MIGAL 2020. system. plans to use an oral vaccine.

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Drug Name/ Product Company Overview/Highlights History Timeline Clinical phase Sources Platform Type The ADDomer platform’s use of University of This method uses particles Vaccine – synthetic virus-like Company Bristol similar in structure to SARS-CoV- No timeline Not yet in ADDomer Virus-like particles would Announcement / 2 to trigger immune response to announced. clinical trials particles ensure that a vaccine Media Imophoron protect against the virus. doesn’t cause re- infections. Received a $10.3 No No Tulane million grant for No timeline Not yet in Company information information No information available. University COVID-19 therapies announced. clinical trials. announcement available. available. and vaccines. IMV specializes in immuno-oncology No timeline DPX does not provide many therapies and is announced, but DPX Vaccine – details about the mode of action, Not yet in Company IMV seeking grant seeking to begin platform but notes that the DPX platform clinical trials. announcement funding in Canada phase 1 trials in focuses on T-Cell stimulation. for its vaccine summer 2020. candidate.

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple. Last updated April 8, 2020.

First published March 17, 2020

For questions or concerns, please contact the AgencyIQ team:

Alexander Gaffney, RAC Senior Director, Research [email protected]

Kedest Tadesse, MS, RAC Senior Research Manager [email protected]

Laura DiAngelo, MPH Senior Research Manager [email protected]

Lily Rosenfield Research Analyst [email protected]

Aaron Badida, JD Research Analyst [email protected]

agencyiq.com

Last updated 8 April 2020. New updates to this spreadsheet are highlighted in purple.